Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method

Haematologica

Volumn 93, Issue 2, 2008, Pages 215-223

  Gachard, Nathalie ^a   Salviat, Aurélie ^a   Boutet, Catherine ^b   Arnoulet, Christine ^c   Durrieu, Françoise ^d   Lenormand, Bernard ^b   Leprêtre, Stéphane ^e   Olschwang, Sylviane ^c,f   Jardin, Fabrice ^e   Lafage Pochitaloff, Marina ^c,f   Penther, Dominique ^g   Sainty, Danielle ^c,f   Reminieras, Liliane ^h   Feuillard, Jean ^a   Béné, Marie Christine ⁱ  

^a CNRS   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d Lab d'Hematologie Pharmaceut   (France)

^e CLCC Henri Becquerel   (France)

^f INSERM   (France)

^g Laboratoire de Génétique Oncologique   (France)

^h UNIVERSITY OF LIMOGES   (France)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

B cell chronic lymphocytic leukemia; CD38; Prognosis; ZAP 70

Indexed keywords

CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70;

ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FLOW CYTOMETRY; GENE DELETION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION;

ANTIGENS, CD38; BLOOD DONORS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 12; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE GLYCOPROTEINS; MUTATION; PROGNOSIS; TRISOMY; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 40849105146     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11622     Document Type: Article

References (35)

1. Dighiero G. CLL Biology and prognosis. Hematology Am Soc Hematol Educ Program 2005;278-84.
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
3. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
4. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
5. Stilgenbauer S, Lichter P, Dohner H. Genetic features of B-cell chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4:48-72.
6. Montserrat E. Prognosis in chronic lymphocytic leukemia: let's have a look! Haematologica 2002;87:561-2.
7. Montserrat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program 2006; 279-84.
8. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7.
9. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54.
10. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-84.
11. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-6.
12. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103:1202-10.
13. Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 2005;90:391-9.
14. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.
15. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75.
16. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-11.
17. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351:893-901.
18. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005;105:2036-41.
19. Del Principe MI, Del Poeta G, Buccisano F, Maurillo L, Venditti A, Zucchetto A, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006;108:853-61.
20. Letestu R, Rawstron A, Ghia P, Villamor N, Leuven NB, Boettcher S, et al. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: a multicentric international harmonization process. Cytometry B Clin Cytom 2006;70:309-14.
21. Shankey TV, Forman M, Scibelli P, Cobb J, Smith CM, Mills R, et al. An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006;70:259-69.
22. Best OG, Ibbotson RE, Parker AE, Davis ZA, Orchard JA, Oscier DG. ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis. Cytometry B Clin Cytom 2006;70:235-41.
23. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-317.
24. Pekova S, Baran-Marszak F, Schwarz J, Matoska V. Mutated or non-mutated? Which database to choose when determining the IgVH hypermutation status in chronic lymphocytic leukemia? Haematologica 2006;91:ELT01.
25. Valleron A. Probabilité et Statistique. Paris, Masson, 2001.
26. Boyd JC. Mathematical tools for demonstrating the clinical usefulness of biochemical markers. Scand J Clin Lab Invest Suppl 1997;227:46-63.
27. Zucchetto A, Bomben R, Bo MD, Nanni P, Bulian P, Rossi FM, et al. ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations. Cytometry B Clin Cytom 2006;70:284-92.
28. Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003;17:2426-34.
29. Krober A, Bloehdorn J, Hafner S, Buhler A, Seiler T, Kienle D, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969-75.
30. Gowda A, Byrd JC. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol 2006;13:266-72.
31. Scielzo C, Camporeale A, Geuna M, Alessio M, Poggi A, Zocchi MR, et al. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia 2006;20:689-95.
32. Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003;17:2426-34.
33. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-51.
34. Wiestner A. More ZAP for chronic lymphocytic leukemia (CLL). Blood 2005;105:1839-40.
35. Wilhelm C, Neubauer A, Brendel C. Discordant results of flow cytometric ZAP-70 expression status in B-CLL samples if different gating strategies are applied. Cytometry B Clin Cytom 2006;70:242-50.